Otsuka Pharmaceutical Companies (U.S.) in the news

Otsuka Pharmaceutical's VOYXACT preserved kidney function and slowed disease progression in adults with primary IgA nephropathy during a 12-month Phase 3 trial.

New Phase 3 clinical data shows centanafadine improves executive function and emotional dysregulation in adults with ADHD, with an FDA target action date set for July 2026.

Otsuka Pharmaceutical is purchasing Transcend Therapeutics for $700 million to expand its drug development capabilities.

Otsuka Pharmaceutical is acquiring Transcend Therapeutics for up to $1.225 billion to obtain a breakthrough PTSD treatment and expand its psychiatric drug pipeline.

Strategic expansion into psychedelics and autoimmune therapies aims to address high unmet medical needs in mental health and nephrology.

Japanese pharmaceutical companies are increasingly acquiring U.S. and European biotech firms to secure new drug pipelines in oncology and immunology.

The FDA approved Otsuka's new drug Voyxact for patients with the autoimmune kidney condition IgA nephropathy.

FDA approval has been granted for the injectable drug Voyxact to treat primary immunoglobulin A nephropathy.

Otsuka Pharmaceutical is acquiring Cantargia's CAN10 antibody program for autoimmune diseases in a deal totaling over $600 million.

Otsuka Pharmaceutical acquired the CAN10 antibody program for autoimmune disease treatment in a deal valued at over $600 million.

Lupin has launched its first-to-file generic version of Otsuka's kidney disease drug Jynarque in the US market.

Otsuka subsidiary Pharmavite has opened a new manufacturing and R&D facility in Ohio to meet growing consumer demand for gummy supplements.

Otsuka North America's CEO is exploring AI and health tech partnerships to improve patient access and streamline data analysis across the pharmaceutical value chain.

Otsuka America launched a new subsidiary, Otsuka Precision Health, to commercialize the first FDA-cleared prescription digital therapeutic for major depressive disorder.

Jane Urban has been appointed as VP of Customer Engagement Operations to lead data-driven and digital strategy transformations.

The schizophrenia drugs market is expanding toward a projected $11.19 billion by 2030 due to rising diagnosis rates and the development of next-generation therapies with fewer side effects.